Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells $250,458.36 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) COO Christina Rossi sold 2,274 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $110.14, for a total value of $250,458.36. Following the sale, the chief operating officer now owns 67,109 shares in the company, valued at $7,391,385.26. The trade was a 3.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Christina Rossi also recently made the following trade(s):

• On Wednesday, December 18th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The stock was sold at an average price of $95.91, for a total transaction of $218,099.34.
• On Wednesday, November 27th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The shares were sold at an average price of $95.10, for a total value of $216,257.40.

Blueprint Medicines Stock Performance

BPMC stock traded up $4.55 during midday trading on Thursday, hitting $115.63. The company's stock had a trading volume of 1,479,676 shares, compared to its average volume of 990,877. The stock has a market cap of $7.35 billion, a price-to-earnings ratio of -54.80 and a beta of 0.61. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The stock's 50-day moving average price is $95.28 and its 200 day moving average price is $95.48. Blueprint Medicines Co. has a 1 year low of $72.24 and a 1 year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.08. The company had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The firm's revenue for the quarter was up 126.5% on a year-over-year basis. During the same quarter last year, the firm posted ($2.20) EPS. On average, equities analysts forecast that Blueprint Medicines Co. will post -3.67 EPS for the current year.

Institutional Investors Weigh In On Blueprint Medicines

Hedge funds have recently bought and sold shares of the stock. Amalgamated Bank grew its holdings in shares of Blueprint Medicines by 5.3% during the 2nd quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company's stock valued at $232,000 after purchasing an additional 109 shares during the last quarter. Pallas Capital Advisors LLC grew its stake in shares of Blueprint Medicines by 3.2% during the third quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company's stock valued at $523,000 after buying an additional 176 shares during the last quarter. Clarus Wealth Advisors increased its holdings in shares of Blueprint Medicines by 8.6% in the third quarter. Clarus Wealth Advisors now owns 2,590 shares of the biotechnology company's stock worth $231,000 after buying an additional 206 shares during the period. Mackenzie Financial Corp lifted its stake in shares of Blueprint Medicines by 5.2% in the 2nd quarter. Mackenzie Financial Corp now owns 4,885 shares of the biotechnology company's stock valued at $527,000 after acquiring an additional 243 shares during the last quarter. Finally, Franklin Resources Inc. boosted its holdings in Blueprint Medicines by 0.7% during the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock valued at $3,259,000 after acquiring an additional 265 shares during the period.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on BPMC shares. Needham & Company LLC reissued a "buy" rating and set a $135.00 price target on shares of Blueprint Medicines in a research note on Monday, January 13th. JPMorgan Chase & Co. initiated coverage on shares of Blueprint Medicines in a research report on Thursday, November 14th. They set an "overweight" rating and a $126.00 target price for the company. Wells Fargo & Company reduced their price target on Blueprint Medicines from $153.00 to $151.00 and set an "overweight" rating on the stock in a research report on Thursday, October 31st. Wedbush reiterated an "outperform" rating and issued a $124.00 price objective (down previously from $135.00) on shares of Blueprint Medicines in a report on Monday, January 13th. Finally, Guggenheim reissued a "buy" rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Blueprint Medicines presently has an average rating of "Moderate Buy" and a consensus price target of $122.72.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.